AUTHORS
Huayuan Zhu, MD, PhD, Yuexin CHENG, MD2, Xuzhang Lu, PhD3, Xiaoyan Xie4, Bingzong Li, ????5, Ling Gao6, Shuchao Qin, MBBS7, Zongren Zhu8, Yi Xia, MD, PhD9, Lei Cao10, Wenyu Shi11, Jianyong Li, MD12
AFFILIATIONS
1 Jiangsu Cooperative Lymphoma Group, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
2 Jiangsu Cooperative Lymphoma Group, Nanjing, China, The First People's Hospital of Yancheng, Yancheng, China
3 Jiangsu Cooperative Lymphoma Group, Nanjing, China, The Second people’s hospital of Changzhou, The Third affiliated hospital of Nanjing medical university, Changzhou, China
4 Jiangsu Cooperative Lymphoma Group, Nanjing, China, Northern Jiangsu People's Hospital, Yangzhou, China
5 Jiangsu Cooperative Lymphoma Group, Nanjing, China, The Second Affiliated Hospital of Soochow University, Suzhou, China
6 Jiangsu Cooperative Lymphoma Group, Nanjing, China, Jiangsu Provincial (Suqian) Hospital, Suqian, China
7 Jiangsu Cooperative Lymphoma Group, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
8 Tianchang City People's Hospital, Chuzhou, China
9 Jiangsu Cooperative Lymphoma Group, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
10 Jiangsu Cooperative Lymphoma Group, Nanjing, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
11 Affiliated Hhospital of Nantong University, Nantong, China, Jiangsu Cooperative Lymphoma Group, Nanjing, China
12 Jiangsu Cooperative Lymphoma Group, Nanjing, China, Jiangsu Provincial (Suqian) Hospital, Suqian, China, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
ABSTRACT
Background: Marginal zone lymphoma (MZL) is an indolent B-cell malignancy characterized by a relapsing clinical course. Although widely used in the first-line setting and effective in inducing remission, rituximab-based immunochemotherapy is associated with cumulative toxicities, including neuropathy, myelosuppression, and a potential risk of secondary malignancies. Accordingly, there remains a critical unmet need for highly effective, well-tolerated chemotherapy-free treatment for patients with newly diagnosed MZL. Here, we present updated efficacy and safety data from the chemotherapy-free cohort of Optional (NCT07208981), a multicenter, phase 2 two-cohort study evaluating orelabrutinib, zuberitamab, and lenalidomide (OZL) in newly diagnosed MZL.
Methods: Eligible patients aged 18–75 years had histologically confirmed CD20-positive MALT lymphoma, nodal MZL (NMZL), or splenic MZL (SMZL); ≥1 measurable lesion; an ECOG PS of 0–2; and no prior systemic therapy. Eligible disease comprised newly diagnosed stage III–IV nongastric MALT lymphoma or NMZL meeting protocol-defined treatment indications; stage II nongastric MALT lymphoma or NMZL with bulky disease; or SMZL meeting protocol-defined treatment indications. Patients in the chemotherapy-free cohort received orelabrutinib (150 mg once daily on days 1-28), zuberitamab (375 mg/m2 on day 1), and lenalidomide (20 mg on days 1-21) in 28-day cycles for 6 cycles. During the induction phase, tumor responses were assessed on day 1 of cycles 4 (C4D1) and 7 (C7D1) according to the Lugano classification criteria or GELA criteria. Patients achieving a complete response (CR) or partial response (PR) at the end of induction could receive orelabrutinib maintenance for up to 24 cycles or undergo observation at the investigator’s discretion. The primary endpoint was 3-year progression-free survival (PFS) rate. Secondary endpoints included objective response rate (ORR), best overall response (BOR), CR rate (CRR), time to response (TTR), duration of response (DoR), PFS, overall survival (OS), safety, and quality of life.
Results: As of July 28, 2026, 30 patients were treated with OZL, including 9 (30.0%) with EMZL, 7 (23.3%) with NMZL, and 14 (46.7%) with SMZL. The median age was 62.0 years (IQR, 57.2-72.0). Twenty of 30 (66.7%) patients were male. Most patients had stage IV disease (83.3%) and an ECOG performance status of 1 (93.3%). Bone marrow involvement and B symptoms occurred in 21 (70.0%) and 6 (20.0%) patients, respectively. Elevated β2-microglobulin was observed in 14 of 26 evaluable patients (53.8%). Elevated lactate dehydrogenase and bulky disease (≥7.5 cm) were reported in 5 (16.7%) and 3 (10.0%) patients, respectively. Among the 20 patients evaluable for response at C4D1, the ORR was 95.0% (95% CI, 75.1%-99.9%), including 11 CRs (55.0%; 95% CI, 31.5%-76.9%) and 8 PRs (40.0%); 1 patient (5.0%) had stable disease (SD), and none had progressive disease (PD). Response rates were consistently high across histologic subtypes at C4D1, with ORRs of 83.3% (95% CI, 35.9%-99.6%) in EMZL, 100% (95% CI, 54.1%-100%) in NMZL, and 100% (95% CI, 63.1%-100%) in SMZL. Among the 13 patients evaluable for response at C7D1, the ORR was 92.3% (95% CI, 64.0%-99.8%), including 9 CRs (69.2%; 95% CI, 38.6%-90.9%) and 3 PRs (23.1%); 1 patient (7.7%) had SD, and none had PD. At C7D1, all evaluable patients with EMZL achieved CR; both the ORR and CRR were 100% (95% CI, 29.2%-100%). ORR was 100% (95% CI, 39.8%-100%) in NMZL and 83.3% (95% CI, 35.9%-99.6%) in SMZL. Of the 13 patients with bone marrow measurable residual disease (MRD) positivity at baseline who were evaluable at C4D1, 8 (61.5%) achieved MRD negativity. At C7D1, MRD negativity was observed in 7 of 10 patients (70.0%) with baseline bone marrow MRD positivity. Adverse events (AEs) occurred in 21 of 30 (70.0%) patients, and grade ≥3 AEs occurred in 15 (50.0%) patients. The most common AEs were neutrophil count decreased (56.7%), thrombocytopenia (23.3%), and rash (23.3%). Survival and longitudinal quality of life data remain immature.
Conclusions: In patients with newly diagnosed advanced-stage MZL who meet treatment indications, chemotherapy-free OZL regimen exhibited encouraging activity across subtypes, with high response and a manageable safety profile. These preliminary findings support further evaluation of OZL in patients with treatment-naïve MZL. Enrollment and follow-up are ongoing, and updated outcomes will be reported.
DISCLOSURES
Huayuan Zhu, MD, PhD: No relevant conflicts of interest to declare.